SCHEMBL2248317

SCHEMBL2248317

CNc1cc(F)c(C(=O)OC)cc1N

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.46
ATM Q13315 2/20 0.46
POLB P06746 2/20 0.46
GAA P10253 6/20 0.45
ALDH1A1 P00352 5/20 0.45
MAPT P10636 4/20 0.45
HSD17B10 Q99714 3/20 0.45
HPGD P15428 2/20 0.45
TSHR P16473 2/20 0.45
ALOX15 P16050 1/20 0.45
GLA P06280 2/20 0.44
CASP1 P29466 1/20 0.44
CASP7 P55210 1/20 0.44
CFTR P13569 3/20 0.43
ABL1 P00519 1/20 0.42
PRKCI P41743 1/20 0.40
MAPK1 P28482 1/20 0.40
ILK Q13418 1/20 0.38
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23970830 0.86 KDM4E (0.52) KDM4EATMPOLBGAAALDH1A1
SCHEMBL1964928 0.84 ALDH1A1 (0.46) KDM4EPOLBGAAALDH1A1MAPT
SCHEMBL15322951 0.84 KDM4E (0.50) KDM4EATMPOLBGAAALDH1A1
SCHEMBL1509484 0.84 KDM4E (0.52) KDM4EATMPOLBGAAALDH1A1
SCHEMBL22222285 0.83 PRKCI (0.42) KDM4EPOLBGAAALDH1A1MAPT
SCHEMBL3529864 0.82 KDM4E (0.50) KDM4EATMPOLBGAAALDH1A1
SCHEMBL30221910 0.82 KDM4E (0.50) KDM4EATMPOLBGAAALDH1A1
SCHEMBL2900514 0.82 KDM4E (0.59) KDM4EATMPOLBGAAALDH1A1
SCHEMBL973355 0.81 KDM4E (0.49) KDM4EATMPOLBGAAALDH1A1
SCHEMBL31215265 0.81 KDM4E (0.49) KDM4EATMPOLBGAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240409533-A1 HMOX1 INDUCERS Astellas Engineered Small Molecules US, Incorporated 2024-12-12 US disclosed
CN-113874074-B HMOX1 inducers 米托布里奇公司 2024-11-01 CN disclosed
US-12091407-B2 Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof VTV THERAPEUTICS LLC (US) 2024-09-17 US disclosed
US-12071433-B2 HMOX1 inducers Astellas Engineered Small Molecules US, Incorporated (US) 2024-08-27 US disclosed
US-20240051952-A1 HMOX1 INDUCERS Astellas Engineered Small Molecules US, Incorporated 2024-02-15 US disclosed
US-20230312548-A1 SUBSTITUTE FUSED IMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF VTV THERAPEUTICS LLC 2023-10-05 US disclosed
US-11649230-B2 Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof VTV THERAPEUTICS LLC (US) 2023-05-16 US disclosed
US-20220177460-A1 HMOX1 INDUCERS Astellas Engineered Small Molecules US, Incorporated 2022-06-09 US disclosed
US-20220177460-A1 HMOX1 INDUCERS Astellas Engineered Small Molecules US, Incorporated 2022-06-09 US disclosed
US-20220169641-A1 Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof VTVX HOLDINGS II LLC 2022-06-02 US disclosed
US-10570126-B2 Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof VTV THERAPEUTICS LLC (US) 2020-02-25 US disclosed
US-20190194181-A1 Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof TRANSTECH PHARMA, INC. 2019-06-27 US disclosed
US-10287284-B2 Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof VTV THERAPEUTICS LLC (US) 2019-05-14 US disclosed
US-20180291015-A1 Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof TRANSTECH PHARMA, INC. 2018-10-11 US disclosed
US-10030011-B2 Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof VTV THERAPEUTICS LLC (US) 2018-07-24 US disclosed
EP-2536285-B1 SUBSTITUTED FUSED IMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF VTV THERAPEUTICS LLC (US) 2018-04-25 EP disclosed
US-8759535-B2 Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof HIGH POINT PHARMACEUTICALS, LLC (US) 2014-06-24 US disclosed
EP-2536285-A1 SUBSTITUTED FUSED IMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF High Point Pharmaceuticals, LLC (US) 2012-12-26 EP disclosed
WO-2011103018-A1 SUBSTITUTED FUSED IMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF HIGH POINT PHARMACEUTICALS, LLC (US) 2011-08-25 WO disclosed
US-20110201604-A1 Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof HIGH POINT PHARMACEUTICALS, LLC (US) 2011-08-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12091407-B2 Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof GLS, HMOX2, REN KDM4E 2451/4885ATM 3115/4885POLB 2487/4885
US-20220169641-A1 Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof GLS, HMOX2, REN KDM4E 2451/4885ATM 3115/4885POLB 2487/4885
US-20110201604-A1 Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof HMOX2, HMOX1, PTGS2 KDM4E 2243/4885ATM 1498/4885POLB 2190/4885
US-10287284-B2 Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof HMOX2, HMOX1, PTGS2 KDM4E 2243/4885ATM 1498/4885POLB 2190/4885
US-20230312548-A1 SUBSTITUTE FUSED IMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF GLS, HMOX2, REN KDM4E 2332/4885ATM 2765/4885POLB 2872/4885
US-11649230-B2 Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof GLS, HMOX2, REN KDM4E 2451/4885ATM 3115/4885POLB 2487/4885
US-20190194181-A1 Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof HMOX2, HMOX1, UACA KDM4E 2862/4885ATM 2486/4885POLB 1861/4885
US-10030011-B2 Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof HMOX2, HMOX1, PTGS2 KDM4E 2243/4885ATM 1498/4885POLB 2190/4885
US-20240409533-A1 HMOX1 INDUCERS HMOX1, HMOX2, HMBS KDM4E 2510/4885ATM 4608/4885POLB 3184/4885
US-12071433-B2 HMOX1 inducers HMOX1, HMOX2, HMBS KDM4E 2606/4885ATM 4603/4885POLB 2840/4885
US-20240051952-A1 HMOX1 INDUCERS HMOX1, HMOX2, QSOX1 KDM4E 4001/4885ATM 4783/4885POLB 3833/4885
US-20220177460-A1 HMOX1 INDUCERS HMOX1, HMOX2, HMBS KDM4E 2606/4885ATM 4603/4885POLB 2840/4885
US-20180291015-A1 Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof HMOX2, HMOX1, PTGS2 KDM4E 2243/4885ATM 1498/4885POLB 2190/4885
US-10570126-B2 Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof HMOX2, HMOX1, UACA KDM4E 2862/4885ATM 2486/4885POLB 1861/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.